SCHEMBL1246567

SCHEMBL1246567

COc1ccc(C(O)CN(C)C)cc1OC

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 1/20 0.54
PPARD Q03181 1/20 0.54
PPARA Q07869 1/20 0.54
CYP3A4 P08684 1/20 0.50
TSHR P16473 1/20 0.50
NFKB1 P19838 2/20 0.49
SMN1; SMN2 Q16637 1/20 0.48
FDPS P14324 1/20 0.48
BLM P54132 1/20 0.47
PMP22 Q01453 1/20 0.47
KDM4E B2RXH2 1/20 0.47
ALDH1A1 P00352 1/20 0.47
HIF1A Q16665 1/20 0.47
EPAS1 Q99814 1/20 0.47
ACHE P22303 1/20 0.46
AOC3 Q16853 2/20 0.46
KMT2A Q03164 2/20 0.45
CYP1A2 P05177 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17663689 0.89 FDPS (0.49) PPARGPPARDPPARACYP3A4TSHR
Hydrochloric Acid SCHEMBL11275516 0.84 AOC3 (0.50) PPARGPPARDPPARACYP3A4TSHR
Hydrochloric Acid SCHEMBL14775476 0.82 PPARG (0.50) PPARGPPARDPPARACYP3A4TSHR
SCHEMBL6055371 0.82 PPARG (0.61) PPARGPPARDPPARACYP3A4TSHR
SCHEMBL10335590 0.82 PPARG (0.61) PPARGPPARDPPARACYP3A4TSHR
SCHEMBL27817748 0.82 PPARG (0.47) PPARGPPARDPPARACYP3A4TSHR
SCHEMBL22785859 0.80 CYP3A4 (0.74) PPARGPPARDPPARACYP3A4TSHR
SCHEMBL22785862 0.80 CYP3A4 (0.74) PPARGPPARDPPARACYP3A4TSHR
SCHEMBL1655319 0.80 CYP3A4 (0.74) PPARGPPARDPPARACYP3A4TSHR
SCHEMBL20630765 0.79 AOC3 (0.46) PPARGPPARDPPARACYP3A4FDPS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250360137-A1 ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES FREEDOM BIOSCIENCES INC (US) 2025-11-27 US claimed
EP-4618980-A1 ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES Freedom Biosciences, Inc. (US) 2025-09-24 EP claimed
WO-2024107445-A1 ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES FREEDOM BIOSCIENCES, INC. (US) 2024-05-23 WO claimed
US-20180125992-A1 DRUG DELIVERY CONJUGATES OF TERTIARY AMINE CONTAINING DRUGS ENDOCYTE, INC. 2018-05-10 US claimed
US-9435816-B2 Deuterium free, stable isotope labeled 2-phenylethylamine hallucinogens and/or stimulants, methods of their preparation and their use CHIRON AS (NO) 2016-09-06 US claimed
US-20140227792-A1 DEUTERIUM FREE, STABLE ISOTOPE LABELED 2-PHENYLETHYLAMINE HALLUCINOGENS AND/OR STIMULANTS, METHODS OF THEIR PREPARATION AND THEIR USE CHIRON A/S (NO) 2014-08-14 US claimed
WO-2013112040-A1 USE OF CERTAIN TRIOXYGENATED BENZENE DERIVATIVES IN BODY FAT MANAGEMENT BIOTROPICS MALAYSIA BERHAD (MY) 2013-08-01 WO claimed
WO-2013014287-A2 DEUTERIUM FREE, STABLE ISOTOPE LABELED 2-PHENYLETHYLAMINE HALLUCINOGENS AND/OR STIMULANTS, METHODS OF THEIR PREPARATION AND THEIR USE CHIRON AS (NO) 2013-01-31 WO claimed
EP-2551675-A1 Deuterium free, stable isotope labeled 2-phenylethylamine hallucinogens and/or stimulants, methods fo their preparation and their use Chiron AS (NO) 2013-01-30 EP claimed
US-20260083759-A1 Combinations Comprising Psychedelics for the Treatment of Schizophrenia and Other Neuropsychiatric and Neurologic Disorders HADASIT MED RES SERVICE (IL) 2026-03-26 US disclosed
US-20250360137-A1 ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES FREEDOM BIOSCIENCES INC (US) 2025-11-27 US disclosed
EP-4618980-A1 ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES Freedom Biosciences, Inc. (US) 2025-09-24 EP disclosed
EP-4583858-A1 COMBINATIONS COMPRISING PSYCHEDELICS FOR THE TREATMENT OF SCHIZOPHRENIA AND OTHER NEUROPSYCHIATRIC AND NEUROLOGIC DISORDERS Hadasit Medical Research Services&Development Ltd. (IL) 2025-07-16 EP disclosed
WO-2025099725-A1 CONJUGATES AND USES THEREOF HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) 2025-05-15 WO disclosed
US-20120195870-A1 PREPARATIONS WITH WOOD EXTRACTS OF LOCUST TREES SYMRISE AG (DE) 2012-08-02 US disclosed
US-20110034486-A1 USE OF PTEROCARPANS AS ACTIVE ANTI-CELLULITE INGREDIENTS SYMRISE GMBH & CO., KG (DE) 2011-02-10 US disclosed
WO-2010097479-A2 CYCLOHEXYL CARBAMATE COMPOUNDS AS ACTIVE ANTI-CELLULITE INGREDIENTS SYMRISE GMBH & CO. KG (DE) 2010-09-02 WO disclosed
WO-2010089421-A2 MENTHYL CARBAMATE COMPOUNDS AS ACTIVE ANTI-CELLULITE INGREDIENTS SYMRISE GMBH & CO. KG (DE) 2010-08-12 WO disclosed
US-20090285919-A1 Rice Bran Extracts for Inflammation and Methods of Use Thereof HALPERN, BARUCH 2009-11-19 US disclosed
US-4617409-A Aminomethyltriorganotin compounds, preferably α-mono or disubstituted; and the method of preparation CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 1986-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140227792-A1 DEUTERIUM FREE, STABLE ISOTOPE LABELED 2-PHENYLETHYLAMINE HALLUCINOGENS AND/OR STIMULANTS, METHODS OF THEIR PREPARATION AND THEIR USE PNMT, HTR2C, HTR2A PPARG 723/4885PPARD 295/4885PPARA 515/4885
US-20260083759-A1 Combinations Comprising Psychedelics for the Treatment of Schizophrenia and Other Neuropsychiatric and Neurologic Disorders BDNF, NTRK2, GRIN2A PPARG 1218/4885PPARD 385/4885PPARA 927/4885
US-20180125992-A1 DRUG DELIVERY CONJUGATES OF TERTIARY AMINE CONTAINING DRUGS ABCB11, SLC10A1, ABCB1 PPARG 4259/4885PPARD 4500/4885PPARA 3883/4885
US-20250360137-A1 ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES PDE9A, PDE3A, PDE2A PPARG 2893/4885PPARD 2242/4885PPARA 2629/4885
US-20120195870-A1 PREPARATIONS WITH WOOD EXTRACTS OF LOCUST TREES LCT, CUTA, GLA PPARG 2246/4885PPARD 2552/4885PPARA 2800/4885
US-20110034486-A1 USE OF PTEROCARPANS AS ACTIVE ANTI-CELLULITE INGREDIENTS FABP4, PLIN1, CPT1B PPARG 42/4885PPARD 24/4885PPARA 36/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.